TY  - GEN
AU  - Matulonis,Ursula A
AU  - Sharma,Sudarshan
AU  - Ghamande,Sharad
AU  - Gordon,Michael S
AU  - Del Prete,Salvatore A
AU  - Ray-Coquard,Isabelle
AU  - Kutarska,Elzbieta
AU  - Liu,Hua
AU  - Fingert,Howard
AU  - Zhou,Xiaofei
AU  - Danaee,Hadi
AU  - Schilder,Russell J
TI  - Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
SN  - 1095-6859
PY  - 2013///0206
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Aurora Kinases
KW  - Azepines
KW  - adverse effects
KW  - Disease-Free Survival
KW  - Fallopian Tube Neoplasms
KW  - drug therapy
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Ovarian Neoplasms
KW  - Peritoneal Neoplasms
KW  - Protein Kinase Inhibitors
KW  - therapeutic use
KW  - Protein Serine-Threonine Kinases
KW  - antagonists & inhibitors
KW  - Pyrimidines
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.ygyno.2012.06.040
ER  -